PASH syndrome with Etanercept treatment, a case report
Keywords:
PASH syndrome, pyoderma gangrenosumAbstract
PASH syndrome is a rare condition that consists of pyoderma gangrenosum (PG), acne and suppurative hidradenitis. It is described as an auto-inflammatory disorder in the same spectrum of PAPA syndrome (pyoderma, acne and pyogenic arthritis). The mainstay of the treatments are immunosuppressive drugs. Tumor necrosis factor α (TNF- α) inhibitors have been reported some benefits in patients with PASH syndrome. We present the case of a 20-year-old man who developed severe acne, ulcers, abscess formations and draining sinuses on the face, neck, trunk, intertriginous areas and extremities. He was ultimate diagnosed with concurrent PASH syndrome. The diseases remitted in response to treatment with etanercept.
References
2. Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 2013;149:762-4.
3. Saraceno R, Babino G, Chiricozzi A, Zangrilli A, Chimenti S. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. J Am Acad Dermatol 2015;72:e42-4.
4. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012;66:409-15.
5. Marzano AV, Ceccherini I, Gattorno M, et al. Association of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) SharesGenetic and Cytokine Profiles With Other Autoinflammatory Diseases. Medicine (Baltimore) 2014; 93: e187.
6. Duchatelet S, Miskinyte S, Join-Lambert O, Ungeheuer MN, Francès C, Nassif A, et al. First nicastrin mutation in PASH (pyoderma gangrenosum, acne and suppurative hidradenitis) syndrome. Br J Dermatol 2015;173:610-2.
7. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenicarthritis, pyoderma gangrenosum and acne)syndrome with the recombinant human interleukin-1 receptor antagonist anakinra,” Br J Dermatol 2009;161:1199–201.
8. Staub J, Pfannschmidt N, Strohal R, et al. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. J Eur Acad Dermatol Venereol 2015; 29: 2243-7.
9. Lowell A. Goldsmith, Stephen I. Katz, et al. Systemic autoinflammatory disease. Fitzpatrick’s dermatology in general medicine. 8th ed:1594- 95.
10. Groleau PF, Grossberg AL, Gaspari AA. Hidradenitis Suppurativa and Concomitant Pyoderma GangrenosumTreated with Infliximab. Cutis 2015;95:337-42.
11. Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002;11:961–9.
12. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg 2005; 9: 296-302.
13. Dinarello CA. A clinical perspective of IL-1b as the gatekeeper of inflammation. Eur J Immunol 2011;41:1203–17.
14. Tofteland ND, Shaver TS. Clinical efficacy of etanercept for treatment of PAPA syndrome. J Clin Rheumatol 2010; 16: 244-5.
15. Kim FS, Pandya AG. The use of etanercept in the treatment of peristomalpyoderma gangrenosum. Clin Exp Dermatol 2012; 37: 442-3.
Downloads
Published
How to Cite
Issue
Section
License
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นลิขสิทธิ์ของวารสารฯ หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักอักษรจากบรรณาธิการวารสารโรคผิวหนังก่อนเท่านั้น
